Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: suloctidil, terodiline, gabapentin +17 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 2 Parkinson's papers of 292 | 0.85 |
| pathways Reactome | 3 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 2627
Sealed predictions
- CACNA1H in dopamine neurons, braak-0.55 (p 0.122) → +0.07 (p 0.849)receipt 2634
Swarm cases
receipt 2634: CACNA1H in dopamine neurons, braak
- power
- full sample -0.28 (p 0.254, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.211, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.170, n 18). could be the mix.
- skeptic
- leave-one-out range -0.39 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.254, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CACNA1H in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts